The NEW Ozempic Replacements: Retatrutide, Orforglipron & Maritide EXPLAINED!
A short overview from a lifestyle medicine channel of three upcoming weight loss drugs, retatrutide, orforglipron and maritide, with the host's take on how each works and which may arrive first.
With Dr. G
Key moments
Tap a moment to play the video from there.
- 0:00Framing the next GLP-1 waveDr. G says three new medications could be more powerful than current GLP-1 drugs and previews a claim of up to 24% body weight loss in early trials.
- 1:04Retatrutide as a triple agonistHe explains that it acts on GLP-1, GIP and glucagon receptors, with the glucagon activity raising energy expenditure. He cites early results of up to 24% weight loss in under a year.
- 2:02Side effects and open questionsHe says retatrutide's side effects look like other GLP-1 drugs, and that researchers are asking whether the triple action adds more.
- 2:24Orforglipron as a daily pillHe describes an oral GLP-1 agonist that works like injectable versions and could help people tired of needles. The formula was adjusted to survive the stomach.
- 3:17Sponsored Mochi Health segmentDr. G promotes Mochi Health as a way to access GLP-1 treatment through licensed clinicians, and mentions a $40 discount on the first month through his link.
- 4:38Maritide and amylinHe describes maritide as designed to mimic amylin, and says early trials suggest significant weight loss with potentially fewer side effects. He adds that it is still early.
- 5:40Which could arrive firstHe says orforglipron appears closest to approval because it is furthest along in trials.
- 6:41Bottom line and adviceHe sums up each drug, says none is widely available yet, and tells viewers to focus on what works now. He then promotes his free GLP-1 boot camp.
What the video says
Dr. G, who hosts the channel, introduces three medications he calls the next wave of GLP-1 therapies and says could follow the current injectables. The video is a brief, general-audience overview rather than a walk through trial data, and it includes a sponsored segment for a telehealth service.
He starts with retatrutide, which he describes as a triple agonist acting on the GLP-1, GIP and glucagon receptors, compared with two receptors for tirzepatide. In his account, GLP-1 drugs work mainly by slowing digestion and controlling appetite, GIP may add insulin sensitivity and fat burning, and glucagon activity raises energy expenditure further. He says early studies showed weight loss of up to 24% of body weight in less than a year, against about 15% as the usual figure he cites for comparison. He notes the side effects resemble other GLP-1 drugs, including nausea, vomiting and GI problems, and says researchers are still asking whether the triple action brings more of them.
Next is orforglipron, which he presents as an oral GLP-1 receptor agonist taken as a pill. He says it works like injectable semaglutide by slowing digestion and curbing appetite, that early results are comparable to injectables, and that the formula had to be adjusted to survive the stomach and be absorbed. He argues a pill could help people who stop treatment because of needle fatigue. After the sponsor segment, he turns to maritide, which he describes as designed to mimic amylin, a hormone involved in appetite and blood sugar. He says early trials suggest significant weight loss with potentially fewer side effects, but stresses it is at an early stage and more data is needed.
On timing, he says the oral drug looks closest to approval because it is furthest along in trials. He closes by saying none of the three is widely available yet and advises viewers not to wait for them, pointing instead to a free 14 day GLP-1 boot camp he offers.
On each compound
Retatrutide1:04
Dr. G describes retatrutide as a triple agonist of the GLP-1, GIP and glucagon receptors, with glucagon activity raising energy expenditure. He cites early studies with up to 24% body weight loss in under a year and says side effects resemble other GLP-1 drugs.
See how your DNA reads RetatrutideMariTide4:38
Dr. G says maritide is designed to mimic amylin rather than act only as a GLP-1. He says early trials suggest significant weight loss with potentially fewer side effects, but that it is still early and needs more data.
See how your DNA reads MariTide“don't wait for the next big thing.”
What this video doesn’t settle
- The weight loss figures are given in passing, with no trial names, dose levels, participant groups or sources, so they cannot be checked from the video.
- The claim that maritide may cause fewer side effects than traditional GLP-1 drugs is described as tentative, and no data is shown.
- The host says one of the drugs may work best combined with other therapies, but the video never names which one or what the combination would be.
Questions this video answers
How does retatrutide differ from tirzepatide?
Dr. G says retatrutide acts on three receptors, GLP-1, GIP and glucagon, while tirzepatide acts on two. He says the added glucagon activity raises energy expenditure further.
How much weight loss does Dr. G cite for retatrutide?
He cites early studies in which patients lost up to 24% of their body weight in less than a year. He compares this with about 15% as the usual figure for current drugs.
What is maritide according to this video?
Dr. G describes it as a drug designed to mimic amylin, a hormone that helps regulate appetite and blood sugar. He says early trials suggest significant weight loss with potentially fewer side effects, but that it is still in an early phase.
Which of the new GLP-1 drugs does Dr. G think will be approved first?
He says the oral GLP-1, orforglipron, appears closest to approval because it is furthest along in trials. He says the others are further off.
Video by Dr. G's Lifestyle Medicine Network on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
